Protocol Ledger

NCT06387069 · Phase III · RECRUITING

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Interventional Phase III clinical trial protocol NCT06387069 sponsored by Hutchmed in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-26 Enrollment: 316 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06387069
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)316 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06387069
Protocol FieldVerified Registry Value
NCT IdentifierNCT06387069
Consolidated Lead SponsorHutchmed
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment316 participants (ESTIMATED)
Registered Start Date2024-04-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI